Lyra Therapeutics (LYRA) Projected to Post Quarterly Earnings on Thursday

Lyra Therapeutics (NASDAQ:LYRA) is anticipated to issue its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($1.24) per share and revenue of $0.44 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 13, 2026 at 4:00 PM ET.

Lyra Therapeutics Price Performance

NASDAQ LYRA opened at $1.26 on Thursday. The stock’s 50 day simple moving average is $2.09 and its 200-day simple moving average is $4.40. The company has a market cap of $2.23 million and a PE ratio of -0.05. Lyra Therapeutics has a 1-year low of $0.91 and a 1-year high of $37.50.

Hedge Funds Weigh In On Lyra Therapeutics

A number of institutional investors have recently added to or reduced their stakes in LYRA. DRW Securities LLC acquired a new position in Lyra Therapeutics during the fourth quarter worth $52,000. Citadel Advisors LLC purchased a new position in shares of Lyra Therapeutics during the 3rd quarter worth $128,000. Finally, Bank of America Corp DE boosted its position in shares of Lyra Therapeutics by 33.7% during the 2nd quarter. Bank of America Corp DE now owns 28,542 shares of the company’s stock valued at $256,000 after acquiring an additional 7,190 shares during the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Lyra Therapeutics in a report on Thursday, January 22nd. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $100.00.

About Lyra Therapeutics

Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS).